Septerna (NASDAQ:SEPN) Given New $11.00 Price Target at Wells Fargo & Company

Septerna (NASDAQ:SEPN) had its target price decreased by analysts at Wells Fargo & Company from $14.00 to $11.00 in a report released on Friday, MarketBeat Ratings reports. The brokerage presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 101.83% from the stock’s previous close.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $50.00 price target on shares of Septerna in a research report on Tuesday, February 11th.

Septerna Trading Down 0.9 %

Shares of NASDAQ:SEPN traded down $0.05 during trading on Friday, reaching $5.45. The stock had a trading volume of 80,473 shares, compared to its average volume of 511,085. Septerna has a 52 week low of $4.17 and a 52 week high of $28.99. The firm has a 50-day simple moving average of $9.18.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.05. The company had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.13 million. As a group, analysts forecast that Septerna will post -7.11 EPS for the current fiscal year.

Insider Activity

In other news, CFO Gil M. Labrucherie purchased 5,000 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were bought at an average cost of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the acquisition, the chief financial officer now directly owns 30,000 shares in the company, valued at approximately $175,500. This trade represents a 20.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alan Ezekowitz acquired 7,491 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was acquired at an average cost of $6.35 per share, for a total transaction of $47,567.85. Following the transaction, the director now owns 24,911 shares of the company’s stock, valued at $158,184.85. This represents a 43.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 74,346 shares of company stock worth $439,670 in the last 90 days.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC bought a new position in shares of Septerna during the 4th quarter worth approximately $25,000. New York State Common Retirement Fund bought a new stake in shares of Septerna during the 4th quarter worth about $32,000. Legal & General Group Plc bought a new stake in shares of Septerna during the 4th quarter worth about $42,000. Summit Investment Advisors Inc. bought a new position in Septerna in the 4th quarter valued at about $45,000. Finally, BNP Paribas Financial Markets bought a new position in Septerna in the 4th quarter valued at about $52,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.